Physician profile
Walid Mangal
NPI 1659529055
$8,718.26
in general payments reported to CMS, 2019-2025
18 companies · $462 in 2025
The $462 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,491 · 2020: $2,097 · 2021: $474 · 2022: $901 · 2023: $566 · 2024: $728 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $3,934.68 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $761.16 | 2019-2024 | Eylea, Eylea Hd |
| Sun Pharmaceutical Industries INC. | $661.56 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $525.23 | 2019-2021 | |
| Astellas Pharma US INC | $433.36 | 2023-2025 | Izervay |
| Allergan, INC. | $326.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $289.41 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $267.80 | 2022 | |
| Genentech USA, INC. | $266.94 | 2021-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $256.48 | 2022-2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $245.89 | 2019-2021 | |
| Abbvie INC. | $167.02 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $152.47 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $144.40 | 2024-2025 | Iheezo, Triesence |
| Rayner Intraocular Lenses Limited | $124.99 | 2024 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $117.24 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Mallinckrodt Hospital Products INC. | $24.98 | 2025 | Acthar |
| Vyera Pharmaceuticals, LLC | $17.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Mangal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.